Diagnosis and Treatment > Signs and Symptoms
Search for other papers by Susan Ahern in
Google Scholar
PubMed
Search for other papers by Mark Daniels in
Google Scholar
PubMed
Search for other papers by Amrit Bhangoo in
Google Scholar
PubMed
Summary
In this case report, we present a novel mutation in Lim-homeodomain (LIM-HD) transcription factor, LHX3, manifesting as combined pituitary hormone deficiency (CPHD). This female patient was originally diagnosed in Egypt during infancy with Diamond Blackfan Anemia (DBA) requiring several blood transfusions. Around 10 months of age, she was diagnosed and treated for central hypothyroidism. It was not until she came to the United States around two-and-a-half years of age that she was diagnosed and treated for growth hormone deficiency. Her response to growth hormone replacement on linear growth and muscle tone were impressive. She still suffers from severe global development delay likely due to delay in treatment of congenital central hypothyroidism followed by poor access to reliable thyroid medications. Her diagnosis of DBA was not confirmed after genetic testing in the United States and her hemoglobin normalized with hormone replacement therapies. We will review the patient’s clinical course as well as a review of LHX3 mutations and the associated phenotype.
Learning points:
-
Describe an unusual presentation of undertreated pituitary hormone deficiencies in early life
-
Combined pituitary hormone deficiency due to a novel mutation in pituitary transcription factor, LHX3
-
Describe the clinical phenotype of combined pituitary hormone deficiency due to LHX3 mutations
Search for other papers by Cristina Alvarez-Escola in
Google Scholar
PubMed
Search for other papers by Jersy Cardenas-Salas in
Google Scholar
PubMed
Summary
In patients with active acromegaly after pituitary surgery, somatostatin analogues are effective in controlling the disease and can even be curative in some cases. After treatment discontinuation, the likelihood of disease recurrence is high. However, a small subset of patients remains symptom-free after discontinuation, with normalized growth hormone (GH) and insulin-like growth factor (IGF1) levels. The characteristics of patients most likely to achieve sustained remission after treatment discontinuation are not well understood, although limited evidence suggests that sustained remission is more likely in patients with lower GH and IGF1 levels before treatment withdrawal, in those who respond well to low-dose treatment, in those without evidence of adenoma on an MRI scan and/or in patients who receive long-term treatment. In this report, we describe the case of a 56-year-old female patient treated with lanreotide Autogel for 11 years. Treatment was successfully discontinued, and the patient is currently disease-free on all relevant parameters (clinical, biochemical and tumour status). The successful outcome in this case adds to the small body of literature suggesting that some well-selected patients who receive long-term treatment with somatostatin analogues may achieve sustained remission.
Learning points:
-
The probability of disease recurrence is high after discontinuation of treatment with somatostatin analogues.
-
Current data indicate that remission after treatment discontinuation may be more likely in patients with low GH and IGF1 levels before treatment withdrawal, in those who respond well to low-dose treatment, in those without evidence of adenoma on MRI, and/or in patients receiving prolonged treatment.
-
This case report suggests that prolonged treatment with somatostatin analogues can be curative in carefully selected patients.